[go: up one dir, main page]

WO2012030308A3 - Formulation comprising cellobiose - Google Patents

Formulation comprising cellobiose Download PDF

Info

Publication number
WO2012030308A3
WO2012030308A3 PCT/TR2011/000198 TR2011000198W WO2012030308A3 WO 2012030308 A3 WO2012030308 A3 WO 2012030308A3 TR 2011000198 W TR2011000198 W TR 2011000198W WO 2012030308 A3 WO2012030308 A3 WO 2012030308A3
Authority
WO
WIPO (PCT)
Prior art keywords
cellobiose
formulation
copd
asthma
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2011/000198
Other languages
French (fr)
Other versions
WO2012030308A2 (en
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP11776267.4A priority Critical patent/EP2611431A2/en
Publication of WO2012030308A2 publication Critical patent/WO2012030308A2/en
Publication of WO2012030308A3 publication Critical patent/WO2012030308A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a pharmaceutical composition comprising a carrier and one or more than one active agents developed in order to be used in the treatment of respiratory tract diseases such as asthma and COPD.
PCT/TR2011/000198 2010-09-01 2011-08-24 Formulation comprising cellobiose Ceased WO2012030308A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11776267.4A EP2611431A2 (en) 2010-09-01 2011-08-24 Formulation comprising cellobiose

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/07250 2010-09-01
TR2010/07250A TR201007250A2 (en) 2010-09-01 2010-09-01 Formulation containing cellobiose.

Publications (2)

Publication Number Publication Date
WO2012030308A2 WO2012030308A2 (en) 2012-03-08
WO2012030308A3 true WO2012030308A3 (en) 2012-08-09

Family

ID=44883366

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000198 Ceased WO2012030308A2 (en) 2010-09-01 2011-08-24 Formulation comprising cellobiose

Country Status (3)

Country Link
EP (1) EP2611431A2 (en)
TR (1) TR201007250A2 (en)
WO (1) WO2012030308A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014007766A1 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
DE202016008304U1 (en) 2015-01-22 2017-07-05 Pfeifer & Langen GmbH & Co. KG Cellobiose in compositions for consumption or ingestion
IT201900008340A1 (en) * 2019-06-07 2020-12-07 Genetic S P A MONTELUKAST SALTS AND THEIR PHARMACEUTICAL COMPOSITIONS

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089491A1 (en) * 2000-05-19 2001-11-29 Astrazeneca Ab Novel process
US6482429B1 (en) * 2001-06-20 2002-11-19 Boehringer Ingelheim Pharmaceuticals, Inc. Stable powder inhalation dosage formulation
WO2003088944A1 (en) * 2002-04-13 2003-10-30 Glaxo Group Limited Dry powder inhalant composition
WO2005004853A1 (en) * 2003-07-08 2005-01-20 Aventis Pharma Limited Dry powder for inhalation comprising a formoterol salt and ciclesonide
WO2005004846A1 (en) * 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations
US20060147537A1 (en) * 2003-05-28 2006-07-06 Sanofi-Aventis Pharma Limited Stabilized pharmaceutical product

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204826B (en) 1986-03-04 1989-03-10 Chiesi Farma Spa INHALATION PHARMACEUTICAL COMPOSITIONS
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089491A1 (en) * 2000-05-19 2001-11-29 Astrazeneca Ab Novel process
US6482429B1 (en) * 2001-06-20 2002-11-19 Boehringer Ingelheim Pharmaceuticals, Inc. Stable powder inhalation dosage formulation
WO2003088944A1 (en) * 2002-04-13 2003-10-30 Glaxo Group Limited Dry powder inhalant composition
US20060147537A1 (en) * 2003-05-28 2006-07-06 Sanofi-Aventis Pharma Limited Stabilized pharmaceutical product
WO2005004853A1 (en) * 2003-07-08 2005-01-20 Aventis Pharma Limited Dry powder for inhalation comprising a formoterol salt and ciclesonide
WO2005004846A1 (en) * 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations

Also Published As

Publication number Publication date
TR201007250A2 (en) 2012-03-21
WO2012030308A2 (en) 2012-03-08
EP2611431A2 (en) 2013-07-10

Similar Documents

Publication Publication Date Title
WO2012016889A3 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
IL222268A (en) Substituted pyrrolo-pyridines, pharmaceutical compositions comprising them, combined compositions comprising them and their use in the manufacture of medicaments
IL232308A (en) C0mpounds as modulators of atp-binding cassette transporters, pharmaceutical compositions comprising them and their use in the preparation of medicaments for treating diseases and processes for preparation thereof
WO2012021715A3 (en) Stable formulations of linaclotide
IL217572A (en) 1,3-propanedisulfonic acid esters, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments
WO2012177757A3 (en) Personal care compositions comprising shaped abrasive particles
EP2776059A4 (en) Pharmaceutical compositions containing proteases and methods for the treatment of lysosomal storage diseases
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
WO2011141685A3 (en) Systemic nasal compositions comprising cocoyl proline or at least one of the constituents thereof
WO2011076842A3 (en) Aerosol formulation for copd
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
WO2014007972A3 (en) Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinphrine
WO2011152804A3 (en) Process for dry powder formulations
IL226003A (en) Trans-2-decenoic acid derivative and pharmaceutical agent containing the same
IN2012DN00239A (en)
WO2012064302A3 (en) Improved montelukast formulations
WO2012030308A3 (en) Formulation comprising cellobiose
WO2014064652A3 (en) Stable pharmaceutical composition of peginterferon alpha-2b
WO2011076840A3 (en) Aerosol formulation for copd
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
BR112014004737A2 (en) Ambroxol Hydrochloride Compound Compound and Method of Preparation of Compound
WO2011139249A3 (en) Pharmaceutical composition comprising cefdinir
WO2011093831A3 (en) Effervescent formulations comprising cefprozil as active agent
WO2012007758A3 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11776267

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011776267

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE